evipedia.ai
← Back

Strontium for Health & Longevity

Evidence Review created on 09/25/2026 using AI4L / Opus 5.5

Also known as: Sr, Strontium Ranelate, Strontium Citrate, Strontium Carbonate, Strontium Chloride, Strontium Gluconate, Protelos, Osseor

Motivation

Strontium is a naturally occurring mineral that closely resembles calcium and is taken up into bone. It is of interest to people focused on healthy aging because fragile bones and fractures are a leading cause of lost independence later in life, and strontium is one of the few compounds thought to both slow bone breakdown and support bone building.

A prescription form, strontium ranelate, was used in Europe for over a decade to lower fracture risk in women with thinning bones, before regulators restricted it over concerns about blood clots and heart attacks. Meanwhile, other forms of strontium, mainly strontium citrate, are sold in the United States as over-the-counter bone supplements, even though they were never studied the same way. This split between a studied but restricted drug and a widely available but unstudied supplement is what makes the topic both relevant and contested.

This review examines the evidence on strontium’s effects on bone strength, joint health, and overall healthy lifespan, the cardiovascular and other risks, how the prescription and supplement forms differ, and what the evidence means for health-focused adults.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and narrative academic articles that give a high-level overview of strontium for bone health and its risks.

Rhonda Patrick’s only strontium discussion is a short segment of a members-only Q&A episode whose content is not publicly accessible, so it is not listed. No dedicated strontium content was found from Peter Attia, Andrew Huberman, Chris Kresser, or Lifespan.io; their bone-health material covers exercise, nutrition, and approved drugs rather than strontium. Only four items qualified, so the list was not padded with marginally relevant content.

Grokipedia

Strontium

A broad encyclopedia entry on the element, with sections on its biological role, toxicity of stable strontium, radioactive isotopes, and the therapeutic controversies surrounding strontium ranelate.

Examine

Strontium

Examine’s page covers dosing studied for bone, dental, and topical skin uses, notes that oral evidence comes almost entirely from prescription ranelate, and lists safety cautions and antibiotic interactions.

ConsumerLab

No dedicated ConsumerLab review of strontium exists. Strontium is discussed only within broader bone-health content (its calcium and bone-health supplements review and an osteoporosis question-and-answer page), plus a short warning entry, Serious Cardiovascular Risks Associated with Strontium, Health Canada Warns.

Systematic Reviews

This section lists systematic reviews and meta-analyses on strontium’s fracture, joint, cardiovascular, and skin-reaction outcomes.

Mechanism of Action

Strontium ions resemble calcium, so bone partly treats them as calcium. Main proposed actions:

  • Calcium-sensing receptor activation: strontium stimulates the calcium-sensing receptor (CaSR, a cell-surface sensor of calcium levels) on bone cells, encouraging bone-building osteoblasts to multiply and bone-resorbing osteoclasts to form less and die sooner (Brown, 2003).
  • Shift in bone-signaling balance: it raises osteoprotegerin (OPG, a decoy protein that blocks osteoclast activation) and lowers RANKL (receptor activator of nuclear factor-κB ligand, the main signal that switches osteoclasts on) (Kołodziejska et al., 2021).
  • Incorporation into bone mineral: strontium replaces a small share of calcium in hydroxyapatite (bone’s mineral crystal).

A competing reading holds that the “dual action” is modest: in trials, bone turnover markers moved only slightly, and much of the apparent bone density gain is a scanning artifact, because strontium absorbs X-rays more strongly than calcium (Blake & Fogelman, 2007). On this view, strontium acts mainly as a weak brake on bone resorption.

Pharmacology (strontium ranelate 2 g): about 25% absorbed into the blood (oral bioavailability), markedly less with food or calcium; peak blood level at 3–5 hours; half-life about 60 hours, with stable daily blood levels (steady state) in about two weeks; mostly unbound to blood proteins; not selective, acting as a weaker calcium mimic; not metabolized by liver enzymes such as cytochrome P450 (CYP, the main drug-processing enzyme family); cleared by kidneys and gut; concentrated in bone. The ranelate carrier is considered inactive, so citrate delivers the same ion.

Historical Context & Evolution

Strontium was identified in 1790 in ore from Strontian, Scotland, and isolated by Humphry Davy in 1808. Public awareness long centered on radioactive strontium-90 from nuclear fallout, which is chemically identical but unrelated to the stable, non-radioactive strontium used in supplements.

Medical interest began in the 1950s, when Shorr and Carter reported that strontium lactate added to calcium improved skeletal mineral deposition in patients with bone loss (Shorr & Carter, 1952). Interest faded for decades, partly because high doses caused mineralization defects in animals.

The French company Servier developed strontium ranelate in the 1990s, and large trials led to European approval in 2004 as Protelos/Osseor for postmenopausal osteoporosis, later extended to men. It was never approved in the United States, where strontium citrate and other salts became popular bone supplements.

Opinion shifted as safety data accumulated. Severe skin reactions prompted warnings in 2007. In 2013–2014, pooled trial data showed more heart attacks, and the European Medicines Agency (EMA, the European Union drug regulator) restricted use to patients without cardiovascular disease who cannot use other osteoporosis drugs (EMA referral: Protelos and Osseor). Servier ceased marketing in 2017. Independent analysts argued the harms had been under-reported (Bolland & Grey, 2014), while later large real-world studies found no clear heart-attack excess in screened patients (Ali et al., 2020). Both lines of evidence remain part of the current picture, and the supplement forms remain essentially untested for fractures.

Expected Benefits

High 🟩 🟩 🟩

Fewer Osteoporotic Fractures

Strontium ranelate 2 g/day reduced new vertebral fractures in the SOTI trial of 1,649 women (Meunier et al., 2004) and non-vertebral fractures in the 5,091-woman TROPOS trial (Reginster et al., 2005); both were funded by the manufacturer, Servier. Benefit persisted five years in women over 80 (Seeman et al., 2010) and extended to milder bone loss (Seeman et al., 2008), in Servier-funded analyses. A Servier-funded trial in men showed similar bone density gains (Kaufman et al., 2013) without fracture data. No fracture trial has tested strontium citrate.

Magnitude: Vertebral fracture risk fell 41% over 3 years (relative risk, the event rate on treatment divided by the rate on placebo, 0.59; 95% confidence interval, the range likely to contain the true effect, 0.48–0.73); non-vertebral fractures fell 16%, and hip fractures 36% in a high-risk subgroup aged 74 or older.

Medium 🟩 🟩

Slower Knee Osteoarthritis Progression

In the Servier-funded SEKOIA trial of 1,683 people with knee osteoarthritis, strontium ranelate slowed loss of joint-space width on X-ray over three years (Reginster et al., 2013). At 2 g/day, it also modestly improved the WOMAC score (Western Ontario and McMaster Universities Osteoarthritis Index, a validated questionnaire of pain, stiffness, and function). A network meta-analysis (pooling trials of many drugs) confirmed a structural but not a clear symptomatic benefit (Yang et al., 2021). The possible anti-osteoarthritis effect may come from actions on the bone beneath cartilage.

Magnitude: Joint-space narrowing was reduced by 0.10–0.14 mm versus placebo over 3 years (roughly 27–38% less narrowing), with a small WOMAC total-score improvement at 2 g/day (p=0.045, a result unlikely to be due to chance alone).

Low 🟩

Relief of Dentin Hypersensitivity ⭕️ Not Central to Health & Longevity ⚠️ Conflicted

Strontium toothpastes target dentin hypersensitivity (sharp pain from an exposed inner tooth layer); this bears on dental comfort, not bone or lifespan. Individual trials reported relief, but pooled analysis found no effect versus placebo (Bae et al., 2015). On balance, strontium toothpastes show no reliable benefit.

Magnitude: Standardized mean difference (effect size in standard-deviation units) 0.05 (95% confidence interval −0.34 to 0.44) across four placebo-controlled trials, meaning no measurable effect.

Reduced Skin Itch and Irritation ⭕️ Not Central to Health & Longevity

Topical strontium salts dampen sensory nerve firing in skin; this bears on itch and skin comfort, not bone or lifespan. A double-blind trial in 8 volunteers found 20% strontium nitrate shortened histamine-induced itch (Zhai et al., 2000).

Magnitude: Itch duration fell from 28.1 to 18.5 minutes versus the inactive base preparation, with lower itch intensity.

Longer Healthy Lifespan

Fewer hip and vertebral fractures could plausibly extend healthy lifespan. A meta-analysis of osteoporosis-drug trials, including strontium ranelate, found lower mortality across four pooled agents (Bolland et al., 2010), while a Danish cohort found no mortality difference versus bisphosphonates (standard bone-loss drugs) (Svanström et al., 2014). Strontium-specific evidence is indirect.

Magnitude: Mortality relative risk 0.89 (95% confidence interval 0.80–0.99) pooled across four fracture-preventing drugs including strontium ranelate; no strontium-specific reduction in mortality has been shown.

Speculative 🟨

Reduced Inflammation and Metabolic Risk

Reviews propose antioxidant and anti-inflammatory effects relevant to blood pressure and blood sugar (Ru et al., 2024). The basis is mainly mechanistic and animal data without controlled human outcomes.

Better Dental Implant Anchoring ⭕️ Not Central to Health & Longevity

Animal studies suggest strontium improves implant anchoring in osteoporotic bone (Lu et al., 2022); this bears on dental implant success, not fractures or lifespan. The basis is animal work only.

Benefit-Modifying Factors

  • Genetic polymorphisms: no gene variant has been shown to change strontium’s bone benefit; variants in the calcium-sensing receptor gene (CASR, which encodes the receptor strontium activates) are a plausible but untested modifier.
  • Baseline bone density and fracture risk: fracture reduction held across low and high baseline 10-year fracture probability (Kanis et al., 2011), in a pooled analysis of manufacturer-funded trial data.
  • Prior bisphosphonate use: earlier treatment with bisphosphonates blunted the bone density response to strontium ranelate, especially in the first year (Middleton et al., 2010).
  • Vitamin D and calcium status: all pivotal trials corrected calcium and vitamin D; benefit without adequate vitamin D is untested.
  • Sex: men show bone density gains similar to women (Kaufman et al., 2013), but fracture reduction is proven only in women; the trial was Servier-funded.
  • Pre-existing conditions: knee osteoarthritis may add a joint benefit; reduced kidney function raises blood strontium without proven added benefit.
  • Age: women over 80 retained fracture reduction over five years (Seeman et al., 2010), in a Servier-funded analysis.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Venous Thromboembolism ⚠️ Conflicted

Strontium ranelate increased blood clots in deep veins and lungs (pulmonary embolism) in a Cochrane pooled analysis of the main trials, with excess risk appearing in the first year (O’Donnell et al., 2006). A UK–Spain cohort of over 200,000 people found no excess versus alendronate (Martín-Merino et al., 2018), while a five-country European study found 25–30% excess (Ali et al., 2020). Net reading: the trial signal is credible, and the risk is likely smaller in people screened for clot risk.

Magnitude: Venous thromboembolism 2.2% versus 1.5% over 3–4 years (odds ratio, a measure of relative odds similar to relative risk, 1.5; 95% confidence interval 1.1–2.1); pulmonary embolism 0.8% versus 0.4%.

Gastrointestinal Upset

Nausea, diarrhea, and loose stools were the most common adverse events in controlled trials, usually starting early and fading within about three months. The Cochrane review found diarrhea increased with 2 g daily without more treatment withdrawals (O’Donnell et al., 2006). Effects are mild and reversible.

Magnitude: Diarrhea relative risk 1.38 (95% confidence interval 1.02–1.87) with 2 g/day versus placebo.

Medium 🟥 🟥

Heart Attack and Cardiovascular Death ⚠️ Conflicted

An independent re-analysis of regulatory documents showed that pooled data from seven trials found more heart attacks with strontium ranelate, never reported in the trial papers (Bolland & Grey, 2014). Large observational studies found no excess heart attacks (Cooper et al., 2014, Servier-funded; Svanström et al., 2014), though a five-country study found 35% more cardiovascular deaths versus bisphosphonates (Ali et al., 2020). Net reading: a real but modest risk, concentrated in people with existing cardiovascular disease.

Magnitude: In the 5-year TROPOS data, 58 versus 30 heart attacks (relative risk 1.9, 95% confidence interval 1.2–3.0).

Neurological Adverse Events

Headache, seizures, memory loss, and disturbed consciousness were slightly more common with 2 g daily in a Cochrane review’s pooled trial data (O’Donnell et al., 2006). Differences were small and imprecise; mechanism unknown.

Magnitude: Headache 3.9% versus 2.9%; seizures 0.3% versus 0.1%; memory loss 2.4% versus 1.9%.

Low 🟥

Severe Skin Hypersensitivity Reactions

Rare but potentially fatal reactions, including DRESS (drug reaction with eosinophilia and systemic symptoms, a multi-organ allergic reaction) and Stevens-Johnson syndrome (severe blistering skin and mucosal reaction), typically within 3–6 weeks. Evidence comes from case series and post-marketing safety reports (Chen et al., 2021).

Magnitude: By November 2007, 16 DRESS cases, 2 of them fatal, had been reported over about 570,000 patient-years of worldwide use (EMA, 2007); spontaneous reporting likely undercounts true incidence.

Impaired Bone Mineralization at High Exposure

Very high strontium exposure displaces calcium and impairs mineralization. Children in villages with strontium-rich soil had more rickets (soft, deformed bones) (Özgür et al., 1996), and dialysis patients accumulating strontium show osteomalacia (softened bone). Data are ecological (comparing whole communities, not individuals) or indirect.

Magnitude: Rickets prevalence 31.5% versus 19.5% in high- versus low-soil-strontium villages.

Inflated Bone Density Readings

Because strontium absorbs X-rays more strongly than calcium, bone density scans (DXA, dual-energy X-ray absorptiometry) overstate bone mineral (Blake & Fogelman, 2007). Evidence is theoretical modelling and animal-derived corrections; the resulting harm, false reassurance and delayed treatment, has no human outcome data. Readings stay distorted for years after stopping.

Magnitude: About 10% overestimation for every 1% of bone calcium atoms replaced by strontium (1 mol%); a correction analysis of trial data estimated that about 75–80% of the spine bone density gain over 1–3 years reflects bone strontium rather than new bone, with wide uncertainty (Blake & Fogelman, 2007, correction analysis).

Speculative 🟨

Risk-Modifying Factors

  • HLA-A*33:03 carriers: this immune gene variant, common in East Asian populations, sharply raises the risk of strontium-induced Stevens-Johnson syndrome (Chen et al., 2021).
  • Inherited clotting disorders: factor V Leiden and prothrombin gene variants (which make blood clot more easily) plausibly add to strontium’s clot risk.
  • Baseline biomarkers: creatinine clearance (a measure of kidney filtering) below 30 mL/min, high blood pressure, and adverse lipid profiles increase exposure or cardiovascular risk.
  • Sex: women using estrogen therapy carry additive clot risk; the male osteoporosis trial showed a cardiac-event imbalance (Bolland & Grey, 2014).
  • Pre-existing conditions: prior clots, heart disease, stroke, peripheral arterial disease (narrowed leg arteries), immobilization, and chronic kidney disease raise risks.
  • Age: clot risk rises steeply after 80, the same group with the greatest fracture benefit.

Key Interactions & Contraindications

  • Tetracycline and quinolone antibiotics (doxycycline, minocycline, ciprofloxacin, levofloxacin): strontium binds these drugs in the gut, reducing antibiotic absorption and effectiveness. Severity: avoid co-administration; mitigation: strontium is paused for the antibiotic course.
  • Calcium-containing products and dairy (calcium carbonate, calcium citrate, milk): reduce strontium absorption by roughly 60–70%. Severity: monitor/timing; mitigation: a gap of at least 2 hours, with strontium at bedtime.
  • Over-the-counter aluminum or magnesium hydroxide antacids (Maalox, Mylanta): reduce strontium absorption, lowering effectiveness. Severity: caution; mitigation: antacids taken at least 2 hours after strontium.
  • Estrogen-containing therapies and selective estrogen receptor modulators (SERMs, drugs that act like estrogen in some tissues) (estradiol, raloxifene, tamoxifen): additive clot risk. Severity: caution; mitigation: clot-risk assessment before combining.
  • Mineral supplements (iron, zinc, magnesium): compete with strontium for absorption, reducing both. Severity: monitor; mitigation: dosing at a different time of day.
  • Additive bone supplements (vitamin D3, vitamin K2, magnesium): additive bone support; used in citrate combination studies. Severity: generally compatible; mitigation: sufficient vitamin D status.
  • Other interventions (bone density scans, calcium blood tests, surgery, long-haul travel): strontium inflates scan results, may interfere with colorimetric (color-based) calcium assays, and immobility raises clot risk. Severity: monitor; mitigation: clinicians are informed, and strontium is stopped during immobilization.

Populations who should avoid Strontium:

  • Current or previous venous thromboembolism (deep vein thrombosis or pulmonary embolism)
  • Temporary or permanent immobilization (e.g., post-surgical bed rest, wheelchair use)
  • Established ischemic heart disease (reduced blood flow to the heart muscle), peripheral arterial disease, or cerebrovascular disease (prior stroke or transient ischemic attack, a brief stroke-like episode)
  • Uncontrolled high blood pressure (persistently ≥140/90 mmHg despite treatment)
  • Severe kidney impairment (creatinine clearance <30 mL/min)
  • Prior DRESS, Stevens-Johnson syndrome, or other severe rash on strontium
  • Pregnancy, breastfeeding, children and adolescents with growing skeletons
  • Phenylketonuria (a genetic inability to process phenylalanine), for ranelate sachets sweetened with aspartame

Risk Mitigation Strategies

  • Cardiovascular screening before starting: blood pressure, lipids, and heart or vascular history are assessed, and strontium is avoided when disease exists, mitigating heart attack and cardiovascular death risk.
  • Clot-risk screening and immobility rules: personal and family clot history is reviewed, and strontium is stopped during immobilization or 3+ days of bed rest, mitigating venous thromboembolism.
  • Rash action plan: strontium is stopped immediately and medical care sought for rash with fever or swollen glands, especially in weeks 3–6, mitigating progression of DRESS or Stevens-Johnson syndrome.
  • HLA-A*33:03 testing: genotyping before starting is an option for people of East Asian ancestry, mitigating severe skin reaction risk.
  • Bedtime dosing on an empty stomach: dosing at least 2 hours after food and calcium; mild diarrhea usually settles within 3 months, mitigating gastrointestinal upset and absorption loss.
  • Correct scan interpretation: the scanning center is informed, the same scanner is used, and strontium correction is applied (about 10% per mol% bone strontium), mitigating false reassurance from inflated readings.
  • Kidney monitoring: estimated glomerular filtration rate (eGFR, a blood-test estimate of kidney filtering capacity) is checked at baseline and yearly, mitigating strontium accumulation and mineralization defects.

Therapeutic Protocol

  • Conventional prescription regimen: strontium ranelate 2 g sachet (about 680 mg elemental strontium) once daily in water, per the European label; restricted since 2014 to people without cardiovascular disease who cannot use other osteoporosis drugs.
  • Integrative supplement regimen: strontium citrate providing 340–680 mg elemental strontium daily, popularized by Life Extension (which sells strontium) and integrative physicians such as Stephen Genuis (Genuis & Bouchard, 2012); untested for fractures.
  • Nightly combination regimen: melatonin 5 mg, strontium citrate 450 mg, vitamin D3 2,000 IU, and vitamin K2 60 mcg nightly, developed by Paula Witt-Enderby’s group at Duquesne University (Maria et al., 2017).
  • Time of day: bedtime, at least 2 hours after the last meal and away from calcium, maximizes absorption.
  • Half-life: about 60 hours; steady blood levels after roughly two weeks, while bone strontium keeps rising for years.
  • Single versus split dosing: a single daily dose is standard; splitting has not been studied and adds food-timing conflicts.
  • Genetic polymorphisms: HLA-A*33:03 carriers and inherited clotting disorders favor avoidance rather than dose change; no variant guides dose.
  • Sex: fracture-proven dosing is from women; men receive the same 2 g ranelate dose based on bone density data.
  • Age: no dose change in older adults; in people over 80, clot risk and kidney function are the main safety considerations.
  • Baseline biomarkers: vitamin D is corrected before starting; creatinine clearance below 30 mL/min excludes use.
  • Pre-existing conditions: cardiovascular or clotting history excludes use; knee osteoarthritis may add rationale; prior bisphosphonate use may slow bone density response.

Discontinuation & Cycling

  • Duration: long-term rather than lifelong; trials ran 3–5 years with unblinded follow-on treatment to 10 years, and continued need is typically reassessed every few years.
  • Withdrawal effects: none known; stopping causes no rebound bone loss comparable to that after denosumab (an injectable osteoporosis drug).
  • Tapering: not needed; strontium can be stopped abruptly, and immediate stopping is appropriate after a clot, chest pain, or rash.
  • Post-stop scans: bone strontium washes out over years, so scan readings fall gradually, reflecting partly the loss of artifact rather than true bone loss.
  • Cycling: not studied and not used for maintaining effect; switching to a bisphosphonate after stopping remains effective.

Sourcing and Quality

  • Prescription ranelate availability: branded Protelos/Osseor is no longer marketed; generic strontium ranelate remains authorized in some European markets for restricted use.
  • Supplement forms: strontium citrate is most common; carbonate, chloride, gluconate, and aspartate also exist. None has human fracture or long-term safety data, and relative absorption versus ranelate is unmeasured in humans.
  • Elemental content labeling: quality labels state elemental strontium separately from the salt weight, since 680 mg elemental strontium requires a much larger salt dose.
  • Third-party testing: quality markers include independent verification (e.g., USP Verified by the United States Pharmacopeia, NSF Certified by NSF International) and a certificate of analysis covering heavy metals.
  • Representative brands: Doctor’s Best Strontium Bone Maker, Life Extension Strontium Caps, and AlgaeCal Strontium Boost are widely sold; none has fracture-outcome data.
  • Stable versus radioactive strontium: supplements contain stable strontium; radioactive strontium-89 and strontium-90 are unrelated to supplement use.

Practical Considerations

  • Time to effect: vertebral fracture reduction appeared within the first year of ranelate; bone density rises within months, but much of that early rise is scanning artifact.
  • Common pitfalls: taking strontium with calcium or dinner, assuming citrate equals ranelate, not telling scanning centers, and reading rising scan values as proof of stronger bone.
  • Regulatory status: strontium ranelate was never approved by the U.S. Food and Drug Administration (FDA); in the United States, strontium salts are sold as dietary supplements without pre-market efficacy review.
  • Regulatory warnings: the EMA restricted ranelate in 2014, and Health Canada warned in 2015 against strontium supplements for people with cardiovascular risk factors.
  • Cost and payer incentives: supplements are inexpensive; generic bisphosphonates cost far less than ranelate did, giving payers such as national health systems an incentive to favor them, a possible structural influence on guidelines.

Interaction with Foundational Habits

  • Sleep: no direct effect; bedtime dosing fits naturally. The nightly melatonin-strontium combination improved sleep quality (Maria et al., 2017), but that is attributed to melatonin rather than strontium.
  • Nutrition: blunting interaction with calcium-rich foods and dairy, which cut absorption by roughly 60–70%; dosing is timed at least 2 hours after meals. Adequate protein, vitamin D, and vitamin K support bone. Dietary strontium comes from seafood, grains, and leafy vegetables.
  • Exercise: no known blunting; resistance and impact training build bone independently and likely complement strontium. Regular movement also counters the immobility that raises strontium-related clot risk, making activity a potentiating habit.
  • Stress management: no known effect on cortisol or stress response; direction none. Indirectly, chronic high cortisol accelerates bone loss, so stress control supports the same bone goal.

Monitoring Protocol & Defining Success

Baseline testing before starting documents bone status, fracture risk, cardiovascular and clotting risk, kidney function, and vitamin D, because strontium’s main risks cluster in people with existing heart, vessel, or kidney problems. A baseline bone density scan serves as the reference point, since later scans will be inflated by bone strontium; protocols use the same scanner for baseline and follow-up.

Ongoing monitoring follows this cadence: blood pressure and symptom review at 1 month and 3 months, then every 6 months; kidney function, vitamin D, and calcium every 6–12 months; bone turnover markers at 3–6 months; and a bone density scan every 1–2 years with strontium correction noted. Success means no new fractures, stable or improving strontium-adjusted bone density, and no cardiovascular, clot, or skin adverse events.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Bone mineral density (DXA spine and hip) T-score ≥ −1.0; stable or rising after strontium correction Tracks bone status T-score (standard deviations from a young-adult average); conventional osteoporosis cut-off is T-score ≤ −2.5; readings inflated about 10% per mol% bone strontium; same scanner each time
Serum 25-hydroxyvitamin D 40–60 ng/mL Supports calcium absorption Conventional sufficiency ≥20–30 ng/mL; no fasting needed; pair with calcium
Serum calcium 9.2–10.0 mg/dL Screens calcium balance Conventional range 8.5–10.5 mg/dL; strontium may interfere with colorimetric (color-based) assays, which the lab needs to know
Creatinine clearance / eGFR eGFR >60 mL/min/1.73 m² Strontium is kidney-cleared Conventional contraindication is creatinine clearance <30 mL/min; recheck yearly
Blood pressure <120/80 mmHg Cardiovascular risk Conventional target <130/80 mmHg; uncontrolled hypertension excludes use; measure seated, morning
Apolipoprotein B (ApoB) <80 mg/dL Cardiovascular risk ApoB (the protein on each artery-clogging lipoprotein particle); conventional labs flag values above about 100–130 mg/dL and often report LDL (low-density lipoprotein) cholesterol only; fasting optional
CTX and P1NP No established target; track change from own baseline Bone turnover response CTX (C-terminal telopeptide, a bone breakdown marker) and P1NP (procollagen type 1 N-propeptide, a bone formation marker); fasting morning sample
Eosinophil count (if rash) <500 cells/µL Screens for DRESS Eosinophils (allergy-related white blood cells); conventional upper limit about 500 cells/µL; check liver enzymes alongside

Qualitative markers:

  • New back pain, height loss, or fractures
  • Calf pain, leg swelling, or sudden breathlessness
  • Chest pain or exertional discomfort
  • Skin rash, fever, or swollen glands
  • Bowel tolerance in the first 3 months
  • Knee pain, stiffness, and walking ability

Emerging Research

  • Hip fracture healing: a phase 4 placebo-controlled trial in 100 adults aged 60+ is testing whether strontium ranelate speeds radiological healing after surgery for proximal femur fragility fracture (a hip fracture from a minor fall) (NCT05712616); status unknown; positive results could strengthen the case for use after fracture.
  • Topical strontium for itch: a recruiting phase 2 trial of 28 patients compares a strontium chloride hydrogel with triamcinolone cream for immunotherapy-related itch (NCT06748404).
  • Strontium dental materials: a recruiting trial of 142 participants tests a strontium-doped bioactive glass adhesive for dentin hypersensitivity (NCT07628712).
  • Real-world cardiovascular safety: a five-country study found 25–30% more clots and 35% more cardiovascular deaths than with bisphosphonates (Ali et al., 2020), evidence that could weaken the case further.
  • Citrate combination therapy: the small nightly melatonin-strontium citrate trial (Maria et al., 2017) awaits larger replication with fracture endpoints, which could strengthen the case for supplement forms.
  • Comparing strontium salts: mouse work comparing ranelate, citrate, and chloride on bone microarchitecture (Tomczyk-Warunek et al., 2024) highlights the unanswered question of whether supplement salts match ranelate in humans.

Conclusion

Strontium is a calcium-like mineral that settles in bone and appears to shift the balance between bone breakdown and rebuilding modestly toward preservation. For health-focused adults, the evidence splits sharply by form. The prescription form has strong trial evidence for fewer spine fractures and some reduction in other fractures, including in the oldest women, plus moderate evidence for slower knee joint wear. The supplement forms sold over the counter share the same active mineral but have no fracture evidence, only small combination studies measuring bone density.

The main risks are blood clots, which are well documented in trials, and heart attacks, where pooled trial data and large real-world studies disagree; harm appears concentrated in people with existing heart or vessel disease or reduced mobility. Rare but serious skin reactions, stomach upset, and bone scans that overstate true bone gains complete the picture. Nothing shows a direct effect on lifespan.

The evidence base is shaped by conflicts of interest: the main trials were funded by the drug’s manufacturer, and some commentary promoting supplements comes from companies that sell them. Independent re-analysis found that harms were under-reported in published trial papers. Insurers and national health systems also had cost reasons to favor cheaper competing drugs. Overall, strontium offers real but modest bone benefits paired with meaningful cardiovascular trade-offs, and the supplement forms rest largely on assumptions carried over from the prescription form.

Top - Benefits - Risks - Protocol